Two Sigma Advisers
AGRX

Two Sigma Advisers’s Agile Therapeutics AGRX Stock Holding History

Two Sigma Advisers’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-19
Closed -$49K – 2758
2021
Q2 		$49K Sell
19
-146
-88% -$481K ﹤0.01% 2384
2021
Q1 		$685K Buy
165
+33
+25% +$178K ﹤0.01% 1863
2020
Q4 		$759K Hold
132
– – ﹤0.01% 1696
2020
Q3 		$801K Buy
132
+43
+48% +$246K ﹤0.01% 1605
2020
Q2 		$493K Buy
89
+50
+128% +$260K ﹤0.01% 1903
2020
Q1 		$147K Buy
+39
New +$224K ﹤0.01% 2246
2019
Q4 		– Sell
-5
Closed -$12K – 2507
2019
Q3 		$12K Buy
+5
New +$12.3K ﹤0.01% 2193

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers's AGRX Position: Q3 2021 in Review

Two Sigma Advisers sold out of Agile Therapeutics (AGRX) in Q3 2021, closing a stake of 19 shares — an estimated $49K sold.

Two Sigma Advisers first reported a position in AGRX in Q3 2019 and held it in 7 quarters. The position peaked at $801K in Q3 2020. 49 funds tracked by Wall St. Rank hold AGRX as of Q3 2021.

  • Two Sigma Advisers reported no remaining Agile Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Two Sigma Advisers sold 19 Agile Therapeutics shares in Q3 2021, an estimated $49K.
  • Two Sigma Advisers first reported a position in Agile Therapeutics in Q3 2019 and held it in 7 quarters.
  • Two Sigma Advisers's Agile Therapeutics position peaked at $801K in Q3 2020.
  • 49 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2021.

Based on Two Sigma Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.